查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1678794

全球无标记检测市场 - 2025 年至 2033 年

Global Label-Free Detection Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 220 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球无标记检测市场规模达到 6.4483 亿美元，预计到 2033 年将达到 12.5149 亿美元，2025-2033 年预测期内的复合年增长率为 7.5%。

无标记检测是一种先进的分析技术，无需萤光、放射性或酵素标记即可测量分子物理性质的变化。它提供有关结合动力学、亲和力和浓度的即时资料，使其广泛应用于药物发现、先导优化和生物製药研究。它简化了工作流程，缩短了检测开发时间，并允许以最少的样品製备来分析复杂的生物样品。

市场动态：

驱动因素与约束因素

对先进药物发现和开发流程的需求不断增长

无标记检测市场受到对先进药物发现和开发流程日益增长的需求的推动。製药和生物技术公司更喜欢这些技术来即时、准确地测量生物分子相互作用，提高资料品质并减少标籤干扰。对生物製药、生物相似药和个人化医疗的关注加速了这些技术的采用，使得对复杂生物分子和标靶治疗的详细分析成为可能。

此外，无标记检测技术透过提供减少伪影的生物相关资料，彻底改变了药物研发。这些方法消除了对染料、标籤或基因改造细胞的需求，从而可以使用天然细胞并更准确地表示生物相互作用。它们还提供增强的灵敏度、即时动力学和多目标分析。应用包括表型筛选、目标识别和验证、命中到先导化合物优化和毒性评估。

灵敏度和检测范围有限

无标记检测技术由于其灵敏度和检测范围有限，在市场上面临挑战。这些系统提供即时分析，但在检测低丰度生物分子或弱分子相互作用时可能会受到影响，尤其是在复杂的生物样本中。这会影响早期生物标记发现、诊断和药物筛选等关键应用的准确性和可靠性。传统的标记检测方法可能仍然是首选，这可能会限制无标记技术在超灵敏检测应用中的采用。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 对先进药物发现和开发流程的需求不断增长
    • 限制
      • 灵敏度和检测范围有限
    • 机会
    • 影响分析

第五章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：依产品类型

  • 仪器
  • 耗材
  • 软体和服务

第 7 章：按技术

  • 表面等离子体共振 (SPR)
  • 生物层干涉测量法（BLI）
  • 等温滴定量热法 (ITC)
  • 差示扫描量热法（DSC）
  • 其他的

第 8 章：按应用

  • 药物研发
  • 结合动力学和热力学
  • 确认点击和潜在客户生成
  • 内源性受体检测
  • 其他的

第 9 章：按最终用户

  • 製药和生物技术公司
  • 学术及研究机构
  • 合约研究组织 (CRO)
  • 其他

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Danaher Corporation
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • PerkinElmer, Inc
  • Agilent Technologies, Inc
  • Sartorius AG
  • Thermo Fisher Scientific Inc
  • Corning Incorporated
  • Bruker Corporation
  • HORIBA, Ltd.
  • Reichert, Inc
  • Malvern Panalytical Ltd
  • Similar data will be provided for each market player.
  • 阿塔纳空军基地
    • 管道产品描述
    • 产品关键绩效指标 (KPI)
    • 主要活动
    • 市场进入时间表
    • 产品渗透率
    • 销售估计和预测
  • 尼可亚
  • 不受束缚的实验室
  • 奈米温度技术有限公司
  • 克瑞普蒂克斯公司
  • 将为每个市场参与者提供类似的资料。

第 13 章：附录

简介目录
Product Code: BT9289

The Global Label-Free detection market reached US$ 644.83 million in 2024 and is expected to reach US$ 1,251.49 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Label-free detection is an advanced analytical technique that measures changes in the physical properties of molecules without the need for fluorescent, radioactive, or enzymatic labels. It provides real-time data on binding kinetics, affinity, and concentration, making it widely used in drug discovery, lead optimization, and biopharmaceutical research. It streamlines workflows, reduces assay development time, and allows for the analysis of complex biological samples with minimal sample preparation.

Market Dynamics: Drivers & Restraints

Growing Demand for Advanced Drug Discovery and Development Processes

The label-free detection market is driven by the increasing demand for advanced drug discovery and development processes. Pharmaceutical and biotechnology companies prefer these technologies for real-time, accurate measurement of biomolecular interactions, improving data quality and reducing label interference. The focus on biopharmaceuticals, biosimilars, and personalized medicine has accelerated the adoption of these technologies, enabling detailed analysis of complex biological molecules and targeted therapies.

Moreover, Label-free detection technologies are revolutionizing drug discovery by providing biologically relevant data with reduced artifacts. These methods eliminate the need for dyes, tags, or genetically modified cells, allowing for native cells and a more accurate representation of biological interactions. They also offer enhanced sensitivity, real-time kinetics, and multi-target profiling. Applications include phenotypic screening, target identification and validation, hit-to-lead optimization, and toxicity assessment.

Limited Sensitivity and Detection Range

Label-free detection technologies face challenges in the market due to their limited sensitivity and detection range. These systems offer real-time analysis but can be compromised when detecting low-abundance biomolecules or weak molecular interactions, especially in complex biological samples. This affects accuracy and reliability in critical applications like early-stage biomarker discovery, diagnostics, and drug screening. Traditional labeled detection methods may still be preferred, potentially limiting the adoption of label-free technologies in ultra-sensitive detection applications.

Segment Analysis

The global label-free detection market is segmented based on product type, technology, application, end user, and region.

The instruments in the product type segment are expected to dominate with the highest market share.

Instruments are crucial in the label-free detection, enabling the real-time study of biomolecular interactions. Advanced instruments like SPR analyzers, BLI systems, and ITC devices accurately measure binding kinetics, affinity, and thermodynamics without fluorescent or radioactive labels. Due to their rapid, reliable, and label-free results, these instruments are increasingly used in drug discovery, lead optimization, and biopharmaceutical development. Innovation in design, automation, and sensitivity enhancement is increasing demand across pharmaceutical, biotechnology, and research sectors.

For instance, in October 2024, Max Planck Institute researchers developed a method for precisely detecting small liquid quantities, down to micromolar levels, with exceptional sensitivity in the near-infrared spectrum. This breakthrough opens doors to advanced, label-free bio-imaging techniques for detecting target molecules in aqueous environments, pushing biomedical applications' boundaries.

Pharmaceutical and biotechnology companies in the end-user segment are the dominating with the highest market share.

The global label-free detection market is primarily driven by pharmaceutical and biotechnology companies, who rely on these technologies for drug discovery, biotherapeutics development, and biologics research. These companies use label-free systems for high-throughput screening, complex biological interactions analysis, and real-time data generation without labeling interferences. As the pharmaceutical industry shifts towards precision medicine, biologics, and small molecule therapeutics, demand for label-free detection technologies is expected to surge, solidifying their position as a primary growth driver.

Geographical Analysis

North America is expected to hold a significant position in the label-free detection market share

North America holds a substantial position in the label-free detection market due to the presence of a robust pharmaceutical and biotechnology sector, significant research investments, and prominent players like Danaher Corporation, Thermo Fisher Scientific, and Agilent Technologies. Also, the region's focus on drug discovery, early technology adoption, and government support for life sciences research fuel market growth. Market players' innovation in the region is a key driver for market growth in North America.

For instance, in February 2024, Agilent Technologies integrated the xCELLigence RTCA HT platform with the BioTek BioSpa 8 Automated Incubator, providing a non-invasive, label-free, kinetic readout of cell proliferation and cytotoxicity, thereby increasing throughput and decreasing sample sizes.

Competitive Landscape

The major global players in the label-free detection market include Danaher Corporation, PerkinElmer, Inc, Agilent Technologies, Inc, Sartorius AG, Thermo Fisher Scientific Inc, Corning Incorporated, Bruker Corporation, HORIBA, Ltd, Reichert, Inc, and Malvern Panalytical Ltd, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Label-Free Detection market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Product Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Demand for Advanced Drug Discovery and Development Processes
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Sensitivity and Detection Range
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Forces Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Instruments*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Consumables
  • 6.4. Software and Services

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Surface Plasmon Resonance (SPR)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bio-layer interferometry (BLI)
  • 7.4. Isothermal Titration Calorimetry (ITC)
  • 7.5. Differential Scanning Calorimetry (DSC)
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Drug Discovery and Development*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Binding Kinetics and Thermodynamics
  • 8.4. Hit Confirmation and Lead Generation
  • 8.5. Endogenous Receptor Detection
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Pharmaceutical and Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Academic and Research Institutes
  • 9.4. Contract Research Organizations (CROs)
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Danaher Corporation*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals, etc.
    • 12.1.5. SWOT Analysis
  • 12.2. PerkinElmer, Inc
  • 12.3. Agilent Technologies, Inc
  • 12.4. Sartorius AG
  • 12.5. Thermo Fisher Scientific Inc
  • 12.6. Corning Incorporated
  • 12.7. Bruker Corporation
  • 12.8. HORIBA, Ltd.
  • 12.9. Reichert, Inc
  • 12.10. Malvern Panalytical Ltd
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. Attana AB*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Nicoya
  • 12.13. Unchained Labs
  • 12.14. Nanotemper Technologies GmbH
  • 12.15. Creoptix AG
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us